LINCOLN, Nebraska (May 16, 2017) — National Research Corporation (NASDAQ:NRCIA and NRCIB) today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 (ten cents) per Class A share and $.60 (sixty cents) per Class B share payable Friday, July 14, 2017, to shareholders of record as of the close of business on Thursday, June 30, 2017.
|
|||
For more than 36 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. The Company’s solutions enable its clients to understand the voice of the customer with greater clarity, immediacy and depth.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8d47a911-1df2-42de-805c-aa9b475d5b0a
Kevin Karas NRC Health 4024722525 [email protected]


Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
Meta Expands AI Training With Employee Activity Tracking Tools
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 



